Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yusuke Kaida

Showing results (71-80 of 86) with videos related to

Pageof 9
Sort By:
BMC Pulmonary Medicine|October 8, 2024
Risk factors for relapse of immune-related pneumonitis after 6-week oral prednisolone therapy: a follow-up analysis of a phase II studyMasato Karayama, Naoki Inui, Yusuke Inoue, et al.
Journal for Immunotherapy of Cancer|July 27, 2023
Six-week oral prednisolone therapy for immune-related pneumonitis: a single-arm phase II studyMasato Karayama, Naoki Inui, Yusuke Inoue, et al.
JTO Clinical and Research Reports|July 4, 2025
Post-discontinuation Survival in Patients With Advanced NSCLC Receiving Immune Checkpoint Inhibitors: A Pooled Analysis of Prospective Cohort StudiesYusuke Inoue, Yoshihiro Kitahara, Masato Karayama, et al.
Cancer Immunology, Immunotherapy : CII|June 6, 2021
Increased serum cholesterol and long-chain fatty acid levels are associated with the efficacy of nivolumab in patients with non-small cell lung cancerMasato Karayama, Naoki Inui, Yusuke Inoue, et al.
Journal of Clinical Medicine|April 30, 2021
Prognostic and Clinical Value of Cluster Analysis in Idiopathic Pleuroparenchymal Fibroelastosis PhenotypesYutaro Nakamura, Kazutaka Mori, Yasunori Enomoto, et al.
Scientific Reports|January 23, 2026
Serum interferon-λ3 as a short-term biomarker of disease control in anti-MDA5-positive dermatomyositis-associated ILDYoshihiro Kitahara, Tomoyuki Fujisawa, Atsuki Fukada, et al.
JAMA Network Open|September 21, 2020
Evaluation of Programmed Death Ligand 1 (PD-L1) Gene Amplification and Response to Nivolumab Monotherapy in Non-small Cell Lung CancerYusuke Inoue, Katsuhiro Yoshimura, Koji Nishimoto, et al.
Scientific Reports|April 1, 2026
Geriatric nutritional risk index in antifibrotic therapy can predict tolerability and mortality riskTakuya Masuda, Yasutaka Mochizuka, Yuzo Suzuki, et al.
Respiratory Investigation|December 18, 2024
Association between the HAL score and the development of progressive pulmonary fibrosis in idiopathic interstitial pneumonia: A prospective observational studyHiromasa Nakayasu, Masato Karayama, Noriyuki Enomoto, et al.
Respiratory Investigation|February 1, 2025
Prevalence and clinical features of progressive pulmonary fibrosis in patients with unclassifiable idiopathic interstitial pneumonia: A post hoc analysis of prospective multicenter registryMasato Kono, Noriyuki Enomoto, Yusuke Inoue, et al.
Pageof 9

Showing results (71-80 of 86) with videos related to

Sort By:
Pageof 9
BMC Pulmonary Medicine|October 8, 2024
Risk factors for relapse of immune-related pneumonitis after 6-week oral prednisolone therapy: a follow-up analysis of a phase II studyMasato Karayama, Naoki Inui, Yusuke Inoue, et al.
Journal for Immunotherapy of Cancer|July 27, 2023
Six-week oral prednisolone therapy for immune-related pneumonitis: a single-arm phase II studyMasato Karayama, Naoki Inui, Yusuke Inoue, et al.
JTO Clinical and Research Reports|July 4, 2025
Post-discontinuation Survival in Patients With Advanced NSCLC Receiving Immune Checkpoint Inhibitors: A Pooled Analysis of Prospective Cohort StudiesYusuke Inoue, Yoshihiro Kitahara, Masato Karayama, et al.
Cancer Immunology, Immunotherapy : CII|June 6, 2021
Increased serum cholesterol and long-chain fatty acid levels are associated with the efficacy of nivolumab in patients with non-small cell lung cancerMasato Karayama, Naoki Inui, Yusuke Inoue, et al.
Journal of Clinical Medicine|April 30, 2021
Prognostic and Clinical Value of Cluster Analysis in Idiopathic Pleuroparenchymal Fibroelastosis PhenotypesYutaro Nakamura, Kazutaka Mori, Yasunori Enomoto, et al.
Scientific Reports|January 23, 2026
Serum interferon-λ3 as a short-term biomarker of disease control in anti-MDA5-positive dermatomyositis-associated ILDYoshihiro Kitahara, Tomoyuki Fujisawa, Atsuki Fukada, et al.
JAMA Network Open|September 21, 2020
Evaluation of Programmed Death Ligand 1 (PD-L1) Gene Amplification and Response to Nivolumab Monotherapy in Non-small Cell Lung CancerYusuke Inoue, Katsuhiro Yoshimura, Koji Nishimoto, et al.
Scientific Reports|April 1, 2026
Geriatric nutritional risk index in antifibrotic therapy can predict tolerability and mortality riskTakuya Masuda, Yasutaka Mochizuka, Yuzo Suzuki, et al.
Respiratory Investigation|December 18, 2024
Association between the HAL score and the development of progressive pulmonary fibrosis in idiopathic interstitial pneumonia: A prospective observational studyHiromasa Nakayasu, Masato Karayama, Noriyuki Enomoto, et al.
Respiratory Investigation|February 1, 2025
Prevalence and clinical features of progressive pulmonary fibrosis in patients with unclassifiable idiopathic interstitial pneumonia: A post hoc analysis of prospective multicenter registryMasato Kono, Noriyuki Enomoto, Yusuke Inoue, et al.
Pageof 9